JNJ has been the subject of a number of other reports. Zacks Investment Research cut Johnson & Johnson from a buy rating to a hold rating in a report on Monday, April 9th. Jefferies Group set a $153.00 target price on Johnson & Johnson and gave the company a buy rating in a report on Friday, April 13th. Vetr cut Johnson & Johnson from a strong-buy rating to a hold rating and set a $124.55 target price for the company. in a report on Monday, March 26th. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the company a hold rating in a report on Monday, January 22nd. Finally, Royal Bank of Canada restated a buy rating on shares of Johnson & Johnson in a report on Tuesday, January 9th. Five analysts have rated the stock with a sell rating, eight have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $142.98.
NYSE JNJ opened at $127.72 on Wednesday. The firm has a market cap of $350,226.03, a PE ratio of 17.50, a price-to-earnings-growth ratio of 2.08 and a beta of 0.74. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.41 and a quick ratio of 1.12. Johnson & Johnson has a twelve month low of $121.11 and a twelve month high of $148.32.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, April 17th. The company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. The business had revenue of $20.01 billion during the quarter, compared to analysts’ expectations of $19.50 billion. Johnson & Johnson had a return on equity of 30.05% and a net margin of 1.58%. The company’s revenue was up 12.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.83 EPS. equities analysts expect that Johnson & Johnson will post 8.11 earnings per share for the current year.
In other news, VP Paulus Stoffels sold 155,342 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $129.86, for a total transaction of $20,172,712.12. Following the sale, the vice president now owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.22% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goodman Financial Corp purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $104,000. Harding Loevner LP purchased a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $106,000. Stelac Advisory Services LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $108,000. IHT Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 46.4% in the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares in the last quarter. Finally, Mountain Capital Investment Advisors Inc purchased a new stake in shares of Johnson & Johnson in the second quarter valued at approximately $124,000. 67.23% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Receives Buy Rating from Deutsche Bank” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2018/04/19/johnson-johnson-jnj-receives-buy-rating-from-deutsche-bank.html.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.